Active Triple Negative Breast Cancer Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Triple-Negative Breast Cancer (TNBC) Clinical Trial?

• Find Trials That Fit — Browse recruiting Triple-Negative Breast Cancer (TNBC) trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Triple-Negative Breast Cancer (TNBC) type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Triple-Negative Breast Cancer (TNBC) Clinical Trial FAQ

What clinical trials are available for metastatic TNBC?

Active trials for metastatic TNBC include: immunotherapy combinations (pembrolizumab-based regimens), sacituzumab govitecan combinations and next-generation Trop-2 ADCs, PARP inhibitors for BRCA1/2-mutated TNBC (olaparib, talazoparib), AKT inhibitors (capivasertib + paclitaxel for PIK3CA/AKT1/PTEN-altered TNBC), and novel agents targeting TROP2, LIV-1, and other TNBC antigens.

Does my BRCA mutation status affect which TNBC trials I can join?

Yes. BRCA1/2 mutations are present in about 10–15% of TNBC patients and significantly expand trial options. PARP inhibitors (olaparib, talazoparib) are FDA-approved for BRCA-mutated metastatic TNBC. Many trials specifically enroll BRCA-mutated patients. Even without BRCA mutations, TNBC patients may qualify for PARP inhibitor trials based on somatic BRCA alterations or homologous recombination deficiency (HRD) testing.

Are there TNBC trials for early-stage (non-metastatic) patients?

Yes. Neoadjuvant (pre-surgery) and adjuvant (post-surgery) trials are very active for early-stage TNBC. Pembrolizumab plus chemotherapy is FDA-approved for early-stage TNBC, and trials are testing additional immunotherapy combinations, PARP inhibitors in the adjuvant setting (for BRCA-mutated disease), and novel approaches in patients who do not achieve a pathologic complete response (pCR) after neoadjuvant therapy.

What does PD-L1 expression mean for TNBC immunotherapy trials?

PD-L1 expression (measured by CPS) predicts response to checkpoint inhibitors in TNBC. Pembrolizumab is approved for PD-L1-positive (CPS ≥ 10) metastatic TNBC. However, not all immunotherapy trials require PD-L1 positivity — some enroll all TNBC patients. Trialify's eligibility questions will ask about your PD-L1 status to help match you to the right trials.

How do I find a TNBC trial near me?

Enter 'triple-negative breast cancer' as your diagnosis on Trialify, along with your prior treatments, BRCA status, and ZIP code. We search ClinicalTrials.gov and present trials ranked by relevance and distance. Each result includes a plain-language eligibility checklist and a doctor-ready summary with the trial's NCT number.

Explore Other Cancer Trial Guides

• Breast Cancer — Breast cancer trials are testing innovative therapies for all subtypes — HER2+, triple-negative (TNBC), and hormone receptor-positive. New options are opening every month at cancer centers across the country.
• HER2-Positive Breast Cancer — HER2-positive breast cancer overexpresses the HER2 protein, making it responsive to targeted therapies. Trials are advancing trastuzumab deruxtecan (T-DXd), tucatinib combinations, and novel HER2-targeted approaches — including emerging options for HER2-low disease.
• Ovarian Cancer — Ovarian cancer trials are investigating PARP inhibitor combinations, antibody-drug conjugates, folate receptor-targeted therapy, and immunotherapy — with studies available for both platinum-sensitive and resistant disease.
• Lung Cancer — Lung cancer is the leading cause of cancer-related death worldwide. Recruiting clinical trials are testing new immunotherapies, targeted therapies, and combination regimens for NSCLC and SCLC patients.